Despite its prolonged disease course compared to other types of lymphoma, most patients eventually succumb to the disease.
hematopoietic stem cell transplantation (HSCT) has been used to treat patients with relapsed or refractory follicular lymphoma. The results from early reports of autologous HSCT have been favorable with a low incidence of transplant-related mortality but, unfortunately, many of these patients still experience relapse of lymphoma. [9] [10] [11] [12] [13] [14] [15] [16] Allogeneic HSCT may offer an advantage over autologous HSCT by exploiting a graft-versus-lymphoma effect. 17 In keeping with this hypothesis, previous reports of allogeneic HSCT for patients with follicular lymphoma have confirmed a low rate of relapse. 10, 12, 14, [18] [19] [20] [21] [22] [23] Despite encouraging results, the experience with allogeneic HSCT for follicular lymphoma remains limited due to both the indolent nature of the disease and the advanced age of the majority of patients when diagnosed. Indeed, several factors may limit the applicability of allogeneic HSCT to a minority of patients with advanced follicular lymphoma and potentially bias results in favor of HSCT over conventional treatments. In most centers, this includes the exclusion of patients over the age of 55 years, as well as the requirement for demonstrating chemosensitive disease before proceeding to HSCT, thus potentially selecting a better risk patient population. Despite these limitations, however, allogeneic HSCT may offer an improved outcome for selected younger patients with advanced follicular lymphoma. Over the past decade, our center has adopted an aggressive allogeneic HSCT approach for patients with progressive follicular lymphoma. This report details the results of a retrospective analysis of the HSCT outcome for this patient population.
Patients and methods

Patients
Between January 1993 and December 2000, 24 patients with progressive (23 patients) or primary refractory (one patient) follicular lymphoma underwent HDCT and allogeneic HSCT at the Queen Elizabeth II Health Sciences Centre (QEII HSC), the quaternary referral center for Atlantic Canada. General eligibility criteria for allogeneic HSCT included: (1) age Ͻ56 years (sibling donor) or Ͻ46 years (unrelated donor); (2) satisfactory pre-transplant organ function including left ventricular ejection fraction Ͼ50%, carbon monoxide diffusing capacity Ͼ50% of pre-dicted with a forced expiratory volume in one second (FEV1s) Ͼ50% of predicted and a measured 24 h creatinine clearance Ͼ60 ml/min; and (3) an ECOG performance status р2. Patients with follicular lymphoma were considered eligible for allogeneic HSCT if they had progressive disease after receiving first line chemotherapy with or without radiotherapy. All relapsed patients demonstrated chemosensitivity, defined as a у50% decrease in the amount of disease after receiving salvage chemotherapy with multi-agent regimens or high-dose single agent cyclophosphamide; one patient had primary refractory disease (IF), defined as Ͻ50% reduction in the amount of disease or disease progression after salvage chemotherapy. This patient had received three courses of multi-agent chemotherapy without further progression (ie stable disease). One additional patient was initially diagnosed with follicular mixed lymphoma, but had evidence of transformation to a diffuse large cell lymphoma at the time of relapse.
Patient characteristics are detailed in Table 1 . There were 19 females and five males with a median age at HSCT of 44 years (range 32-55). Lymph node histology (classified according to the Working Formulation) at HSCT was follicular small cleaved cell (n = 17), follicular mixed cell (n = 6), and follicular mixed cell with transformation to diffuse large cell (n = 1). The median interval from diagnosis to HSCT was 24 months (range 14-96). At the time of transplant, eight patients had stage III disease and 16 patients had stage IV disease; B symptoms were present in eight patients; serum LDH was elevated in five patients. The number of lines of treatment (chemotherapy and/or radiotherapy regimens) prior to transplant was two (n = 12), three (n = 8), four (n = 2), five (n = 1), or six (n = 1), with a median of three. Disease status at time of HSCT was IF (n = 1), first partial remission (1PR, n = 1), first relapse (1REL, n = 6), 2REL (n = 1), 2PR (n = 11), 3PR (n = 3), or 4PR (n = 1). All patients provided written informed consent for treatment and all research studies were approved by the Institutional Review Board at the QEII HSC.
Conditioning regimens
The regimens were predominantly busulfan based. They included: busulfan 12-16 mg/kg and cyclophosphamide 90-120 mg/kg with (n = 3) or without (n = 19) melphalan 100 mg/m 2 ; two patients received fractionated total body irradiation (fTBI) 200 cGy ϫ 6 with either etoposide 60 mg/kg and melphalan 160 mg/m 2 (n = 1) or cyclophosphamide 180 mg/kg (n = 1).
Donors
Stem cell source was a histocompatible sibling in 23 patients and a HLA A, B, C and DR matched unrelated donor (using high resolution DNA typing) in one patient. Stem cells were collected by standard bone marrow harvest (n = 16) or by apheresis of G-CSF-mobilized peripheral blood (n = 8). In instances of ABO blood group incompatibility, red cell and/or plasma depletion of bone marrow was performed utilizing a CS 3000 cell separator. The median total CD34 cell count infused from the peripheral blood or bone marrow was 5.9 ϫ 10 6 /kg recipient body weight (range 3.5-16.8 ϫ 10 6 /kg) and 2.3 ϫ 10 6 /kg recipient body weight (range 1.8-6.5 ϫ 10 6 /kg), respectively (22 patients); CD34 cell counts were not available in two patients receiving bone marrow, but the total nucleated cell count was 2.6 ϫ 10 8 /kg recipient body weight and 3.2 ϫ 10 8 /kg recipient body weight, respectively.
Graft-versus-host disease (GVHD) prophylaxis
GVHD prophylaxis consisted of intravenous cyclosporine A (CsA) and short-course methotrexate (MTX) in all patients. 24 Treatment of acute GVHD consisted of highdose corticosteroids, with the addition of anti-thymocyte globulin (ATG) in those patients not responding to corticosteroids.
Supportive care
All patients were nursed in high-efficiency particulate air (HEPA) filtered, positive-pressure rooms until engraftment (absolute neutrophil count (ANC) Ͼ0.5 ϫ 10 9 /l). Tunneled triple lumen Hickman central venous catheters were employed. Irradiated blood products were administered to keep the morning hemoglobin concentration у80 g/l and morning platelet count у10 ϫ 10 9 /l. CMV negative blood products were administered to CMV seronegative donor/recipient pairs. Infection prophylaxis included lowdose acyclovir in all patients; anti-bacterial prophylaxis was not used, but intravenous antibiotics were initiated for febrile neutropenia. Trimethaprim/sulphamethoxazole was commenced as PCP prophylaxis from the point of engraftment until immunosuppression was discontinued. Anti-fungal prophylaxis was not routinely used, but fluconazole or amphotericin B was used as required for documented or suspected fungal infection. All patients received unfractionated heparin 100 units/kg/24 h as a continuous i.v. infusion for hepatic veno-occlusive disease prophylaxis starting the day prior to the start of HDCT until day +30 post transplant or until hospital discharge, whichever came first.
Assessment of regimen-related toxicity and GVHD
Regimen-related toxicity was evaluated in eight organ systems according to the Seattle criteria. 25 Acute GVHD was
Bone Marrow Transplantation staged and graded according to the Seattle criteria and chronic GVHD according to the Glucksberg criteria. 26 
Response criteria
Complete remission (CR) was defined as the absence of any clinical or radiographic evidence of lymphoma. Partial remission (PR) was defined as a greater than 50% reduction in the size of all measurable lesions including a greater than 50% reduction in bone marrow involvement histologically. Unconfirmed complete remission (CRU) was defined as the persistence but not progression of any measurable lesions that were not thought to represent active lymphoma. All other treatment responses were considered treatment failures. Progression-free survival (PFS) was measured from the day of HSCT until disease relapse, progression or death from any cause. Overall survival (OAS) was calculated from the day of HSCT until death from any cause.
Statistics
Overall survival (OAS), progression-free survival (PFS) and actuarial probabilities of transplant-related mortality, grades II-IV acute GVHD and chronic GVHD were calculated using the methods of Kaplan and Meier.
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Results
Outcome
The Kaplan-Meier transplant-related mortality rate was 21% (95% CI 3-37) (Figure 1 ). Four patients died as a result of multi-organ failure on days +14, +14, +17 and +38 and one patient succumbed to a cerebrovascular accident on day +319. The stem cell source for the four patients who succumbed to early transplant-related mortality was peripheral blood (two patients) and bone marrow (two patients). The patient who died on day +319 had received bone marrow. The remaining 19 patients are alive without evidence of progression (15 CR, 4 CRU) with a median follow-up of 28 months (range 5-91). The OAS and PFS for the patient cohort at 3 years is 78% (95% CI 63-97) (Figure 2 ).
Regimen-related toxicity
Regimen-related toxicity (RRT) was у grade III in one or more organ systems in five patients (21%). The four patients who developed grade IV RRT had been heavily pre-treated and/or had received an intensified conditioning regimen. UPN 293 had received five lines of therapy prior to HSCT and died from hepatic VOD, acute renal failure (ARF) and acute respiratory distress syndrome (ARDS). UPN 301 had received two lines of therapy, was conditioned with etoposide, melphalan and total body irradiation and developed fatal hepatic VOD. UPN 322 had received three lines of therapy prior to being conditioned with cyclophosphamide and total body irradiation; she developed hepatic VOD and ARF. UPN 353 had received three lines of therapy prior to HSCT and died of an infection and ARF.
Graft-versus-host disease
Eight patients developed significant acute GVHD (grade II (seven), grade III (one)). In five patients, acute GVHD has evolved into chronic GVHD. Ten patients developed chronic GVHD, de novo in five patients and quiescent in five patients. The chronic GVHD was extensive in four patients and limited in six patients. The actuarial incidence of acute (grades II-IV) GVHD and chronic GVHD was 34% (95% CI 10-51) and 45% (95% CI 18-63), respectively.
Disease response
Fifteen patients remain alive and in continuous CR. Four patients are alive, but follow-up computed tomographic (CT) imaging studies at 5, 8, 14 and 21 months post HSCT, respectively, have shown non-progressive residual abnormalities. Whole body gallium scanning has shown no pathologic uptake at these sites and therefore these residual abnormalities are presumed to represent fibrotic tissue. Of the five patients who have died from non-relapse causes, two had no evidence of lymphoma at autopsy (UPN 322 and 353) and one was in CR 10.5 months post HSCT (UPN 304).
Discussion
The first large prospective studies of HSCT for progressive low-grade lymphomas were carried out in Boston and in London. 9, 28, 29 These early studies reported 2-year diseasefree survivals (DFS) of 53% and 65%, respectively, in patients who underwent autologous HSCT. Unfortunately, with more prolonged follow-up the majority of patients have relapsed. More recent uncontrolled trials have suggested that HDCT and autologous HSCT may result in long-term progression-free survival, although a survival advantage over conventional therapy was not shown in these studies. 9, 11, 13, 15, 30 Not surprisingly, the major cause of treatment failure in these trials has been recurrent disease and it has been previously shown that re-infusion of malignant cells is likely to be a major contributor to disease relapse. 13, 31, 32 The enthusiasm for autologous HSCT in advanced follicular lymphoma has increased as the relative safety of the procedure has become apparent. In fact, most experienced centers have reported a 100 day transplant-related mortality (TRM) of 5% or less in this patient cohort. 9, [11] [12] [13] [14] [15] [16] Despite the acceptable early TRM, much concern has been raised about late transplant-related complications, particularly the development of myelodysplasia (tMDS) and AML (tAML), which is particularly devastating as the majority of these patients will die of this complication. [33] [34] [35] [36] [37] HDCT and allogeneic HSCT has been less frequently employed to treat progressive follicular lymphoma due to the advanced age of the patient population, the lack of a suitable donor and a general concern regarding the anticipated higher TRM. Despite the increased risk, there are a number of potential benefits to allogeneic HSCT, including the lack of possible tumor contamination of the stem cell graft and the impact of an immunomodulatory 'graft-versus-lymphoma' effect. The existence of this effect is supported by the lower relapse rates reported in the allogeneic setting and the successful use of donor lymphocyte infusions (DLI) for patients with relapsed disease. 17, 38, 39 Indeed, most reports in the literature evaluating the results of allogeneic HSCT for progressive follicular lymphoma have shown relapse rates of 0-20%. 10, 12, 14, 17, [19] [20] [21] [22] [23] However, these results must be interpreted with caution, given the prolonged natural history of follicular lymphoma and the relatively short follow-up in many of those studies.
The results of our study are in keeping with previous reports and no patient has shown disease progression with a median follow-up of 28 months. It could be argued that these results are superior to what would be expected with standard therapy in this heavily pre-treated patient cohort. Previous reports have indicated that for patients with follicular lymphoma progressing after initial chemotherapy, the median duration of a second response to further standard chemotherapy is 12 months and overall survival 4.5 years. 40 Those patients beyond first relapse have an even shorter response duration to salvage therapy. Therefore, the fact that no patient in our current study has progressed after allogeneic HSCT with a median follow-up of over 2 years is encouraging. The TRM of 21% in the current study is also in keeping with previous reports in the literature where the TRM for this patient cohort is 20-40%. 14, 17, [20] [21] [22] [23] Four of the deaths in our study population were due to multi-organ failure that occurred early post-HSCT. In all four cases, the patients had received extensive prior therapy or an augmented conditioning regimen which probably increased their risk of severe regimen-related toxicity. Whether allogeneic HSCT earlier in the disease course would decrease the risk of early TRM is unknown, as few patients have undergone allogeneic HSCT for non-advanced follicular lymphoma.
The relatively high TRM of allogeneic HSCT as compared to autologous HSCT remains problematic and continues to limit the applicability of this therapy. More recently, much interest has been generated regarding the use of non-myeloablative ('mini') allogeneic HSCT in patients with progressive follicular lymphoma as a means of decreasing the regimen-related toxicity while maintaining the immunologic benefit of the treatment. 39, 41 MD Anderson has recently reported their results with non-myeloablative transplants for lymphoid malignancies. 41 Twenty patients underwent this therapy, all of whom achieved a complete remission. There were three TRM deaths. This study would indicate that mini-transplants are feasible in follicular lymphoma, but that further studies are required to more fully evaluate the toxicity and long-term outcome of the procedure.
In conclusion, while comparative studies of allogeneic and autologous HSCT for progressive follicular lymphoma have not shown an overall survival advantage for allogeneic HSCT, progression-free survivals have often been superior in those patients undergoing allogeneic HSCT. It would appear that the immunologic effect of allogeneic stem cells in decreasing the risk of relapse is critical to this superior outcome. However, the associated TRM remains significant and limits the success of this therapy. Newer HSCT strategies such as non-myeloablative allogeneic HSCT require further investigation, but early reports appear promising in reducing early TRM. Finally, follicular lymphomas are recognized to have a long natural history and late relapses are certainly possible. Much longer follow-up will be necessary to more fully evaluate the curative potential of this treatment, and in particular to evaluate patients for chronic GVHD and recurrent infections, which may negatively influence treatment outcome.
